Gout

Los Angeles, CA

77 Gout Trials near Los Angeles, CA

Power is an online platform that helps thousands of Gout patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Rituximab for Gout

Los Angeles, California
This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to recapture response to Methotrexate-Pegloticase.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 1

9 Participants Needed

Skin Patch Monitor for Gout

Los Angeles, California
15 patients with gout \[10 patients no recent urate-lowering therapy (ULT) and 5 patients on stable urate-lowering therapy (ULT)\] will be invited to participate in a standardized meal at the UCLA Human Nutrition Center and a 7-day community follow-up for the measurement of uric acid (and other metabolites) using our Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

15 Participants Needed

BI 3000202 for Aicardi-Goutières Syndrome

Los Angeles, California
This study is open to adults with selected type 1 interferonopathies. People can join the study if they have Aicardi-Goutières syndrome (AGS), Coatomer subunit alpha (COPA) syndrome, Familial chilblain lupus (FCL), or another type 1 interferonopathy with a specific gene mutation. The purpose of this study is to find out how BI 3000202 is tolerated in people with selected type 1 interferonopathies. Participants take a lower dose of BI 3000202 as tablets for 4 weeks. Afterwards, they take a higher dose of BI 3000202 as tablets for 36 weeks. They may continue with the study treatment until every participant has completed 40 weeks of treatment (about 9 months). The participants may also continue their regular treatment for their condition during the study. During this study, participants visit the study site 13 times or more, depending on when they start their participation. The doctors check the health of the participants and note any health problems that could have been caused by BI 3000202.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

18 Participants Needed

Dapansutrile for Gout Flares

Los Angeles, California
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

300 Participants Needed

Pegloticase + Methotrexate for Gout

North Hollywood, California
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

262 Participants Needed

AR882 for Gout

South Gate, California
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

750 Participants Needed

Dotinurad for Gout

Tujunga, California
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

250 Participants Needed

Dotinurad for Gout

Tujunga, California
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

500 Participants Needed

AR882 for Gout

Santa Monica, California
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

750 Participants Needed

Treat-to-Target vs Symptom Management for Gout

Santa Monica, California
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

650 Participants Needed

D-0120 + Allopurinol for Gout

Panorama City, California
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

80 Participants Needed

Tigulixostat for Gout

Lakewood, California
This trial is testing Tigulixostat, a new medication, to see if it can help people with gout by lowering high levels of uric acid in their blood. The study focuses on gout patients who have high uric acid levels, which can lead to painful attacks. By reducing uric acid, Tigulixostat aims to prevent these painful episodes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

2542 Participants Needed

ABP-671 for Gout

Anaheim, California
This trial is testing a new medication called ABP-671 to see if it works better than an existing drug, allopurinol. Allopurinol has been used since 1966 to reduce urate production. The trial focuses on people who might not respond well to current treatments. ABP-671 probably helps reduce uric acid levels in the body.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:19 - 75

580 Participants Needed

Tigulixostat for Gout

Covina, California
This trial is testing Tigulixostat, a medication that may help people with gout by lowering high uric acid levels. The study focuses on gout patients who have too much uric acid in their blood. By reducing uric acid, Tigulixostat aims to prevent or lessen painful gout attacks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

350 Participants Needed

Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer

Los Angeles, California
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

73 Participants Needed

FMT for Autism

Los Angeles, California
The purpose of this study is to find out if transplant of fecal matter (stool), also known as fecal microbiota transplantation (FMT), from a healthy person into the intestines of children and young adults with Autism Spectrum Disorder (ASD). For this study children between the ages of 5-17years will be recruited over 2 years. Children will be recruited who receive an ASD diagnosis using the gold-standard Autism Diagnosis Observation Schedule -2 (ADOS-2) using module 1, 2 or 3 (none, limited or no moderate expressive language). Children diagnosed with these modules of the ADOS-2 may be at greater risk for GI disorders and rigid-compulsive behaviors. Additional assessment of rigid-compulsive behaviors and social communication will be done using the Repetitive Behavioral Scales-Revised (RBS-R) and Social Responsiveness Scale-2 (SRS-2), respectively. KBIT (the Kaufman Brief Intelligence Test) is used at baseline to obtain patient IQ. Total evaluation time is approximately 90 minutes. Following baseline symptom evaluation, a medical exam will be performed to determine whether each child is expressing specific GI symptoms. In addition, parents will fill out the Questionnaire for Pediatric Gastrointestinal Symptoms- Rome III (QPGS-III). Once an ASD diagnosis is confirmed, FMT treatment will be initiated, which typically occurs within 4-6 weeks of the initial diagnosis. Half 50% of the children (n=5) will receive the equivalent of 50 g of stools from a healthy donor into the jejunum through upper endoscopy and the other 50% off children (n=5) will receive Saline solution as Placebo control through upper endoscopy. Subjects will have a total of 5 visits within 24 weeks including phone call follow up on Day 7 after FMT.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:5 - 17

10 Participants Needed

Polyphenol Supplement for Cognitive Impairment

Los Angeles, California
Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs. In this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs. Participants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50+

300 Participants Needed

Gluten Challenge for Celiac Disease

Pasadena, California
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

220 Participants Needed

L-glutamine + Chemotherapy for Pancreatic Cancer

Beverly Hills, California
This study will enroll a total of 16 patients with advanced pancreatic cancer at Cedars-Sinai Medical Center. All subjects will receive combination therapy of gemcitabine, nab-paclitaxel, and L-glutamine. The study investigates what the appropriate dosage of L-glutamine is so that there is the lowest risk of side effects, and whether the supplement will make standard chemotherapy of gemcitabine and nab-paclitaxel more effective in treating advanced pancreatic cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

18 Participants Needed

Endoscopic Fluid Collection for Small Intestinal Conditions

Los Angeles, California
The small intestine is an understudied frontier of microbiome research. While aspiration during endoscopy is considered the gold standard to assess small bowel bacteria, the tools for sterile retrieval are primitive and poorly validated. Endoscopic aspiration is time-consuming and prone to contamination. Inspired by plants' ability to draw water by capillary action, a novel multi-capillary sterile system was designed which is a modified version of the conventional aspiration catheter. The purpose of this study is to examine the time and volume capabilities of this catheter in suctioning various liquids compared to conventional aspiration catheter, in two groups, each includes 23 patients that going under endoscopy at GI lab at Cedars Sinai Medical Center. The investigator will collect up to 2 ml fluid from Duodenum- in first group by using the conventional catheter and in second group by using the capillary catheter. The time collection and the volume of samples in 2 groups will be compared.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

46 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

Donanemab for Early Alzheimer's Disease

Sherman Oaks, California
This trial is testing different doses of donanemab, a drug aimed at helping people with early Alzheimer's disease. Donanemab has shown rapid reduction of brain amyloid in early Alzheimer's disease. The study will look at how often and how severely participants experience a side effect involving brain swelling. Researchers also want to find out which patient characteristics might predict this side effect.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85

1175 Participants Needed

Certolizumab Pegol for Plaque Psoriasis

Los Angeles, California
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17

150 Participants Needed

Deucravacitinib for Sjögren's Syndrome

La Palma, California
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

756 Participants Needed

CBM588 + Nivolumab/Ipilimumab for Kidney Cancer

Duarte, California
This is a single arm open-label phase 1 study evaluating the safety and efficacy of escalating doses of CBM588 in combination with nivolumab and ipilimumab. A standard 3+3 dose escalation schema will be used initially to assess the maximum tolerated dose (MTD) followed by a dose expansion of 10 patients at the MTD to further evaluate safety and efficacy.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

28 Participants Needed

KAN-101 for Celiac Disease

Anaheim, California
This trial tests KAN-101, a new drug for adults with Celiac Disease on a gluten-free diet. Researchers are studying its safety, tolerance, and effects on the body and blood markers after gluten exposure.

Trial Details

Trial Status:Terminated
Trial Phase:Phase 1, 2

126 Participants Needed

MIT-001 for Oral Mucositis Prevention in Head and Neck Cancer Patients

Los Angeles, California
This trial tests MIT-001, a drug that reduces harmful molecules to prevent inflammation, in patients with advanced head and neck cancer undergoing chemoradiotherapy. The goal is to prevent painful mouth sores by protecting cells and blocking inflammation pathways.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

60 Participants Needed

AFM System for Postoperative Recovery in High-Risk Abdominal Surgery

Los Angeles, California
Goal directed fluid therapy (GDFT) or "Personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes. Recently, an "Assisted Fluid Management" (AFM) system has been developed to help ease some of the work associated with GDFT protocol implementation. The AFM system may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This artificial intelligence-based system can suggest administration of fluid boluses, analyse the hemodynamic effects of the bolus, and continually re-assess the patient for further fluid requirements. To date, there are no large outcome study using this AFM system. The primary objective of this trial is thus to evaluate the impact of this AFM system to guide fluid bolus administration on a composite of major postoperative complications in high-risk patients undergoing high-risk abdominal surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2000 Participants Needed

Opioid-Free vs Opioid-Based Anesthesia for Postoperative Recovery

Los Angeles, California
Substituting the administration of opioids with a combination of alternative analgesics, known as opioid-free anesthesia (OFA), is gaining in popularity today and is typically administered as part of a larger multimodal strategy. However, OFA adoption is not as common today as one could expect from the potential benefits of limiting opioid use and patient involvement in the decision may impact its adoption. Relevant shared decision-making process with patients concerning the use or limited use of opioids could improve patient autonomy and empowerment. There have been no studies that have evaluated patient preference regarding opioid use and its potential impact on the quality of recovery. The aim of this study is to compare the effect of patient preference on intraoperative opioid use on early postoperative quality of recovery following moderate risk laparoscopic/robotic abdominal surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

240 Participants Needed

Serial Amnioinfusions for Low Amniotic Fluid

Los Angeles, California
This trial tests a method of injecting fluid into the womb of pregnant women whose fetuses have a severe kidney condition that prevents normal lung development. The goal is to help the fetus's lungs grow so they can survive after birth. The trial focuses on the safety and effectiveness of this treatment for fetuses with urinary tract issues.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:Female

70 Participants Needed

Transcatheter Pulmonary Valve Therapy for Pulmonary Regurgitation

Los Angeles, California
The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™ TPV system. The Pivotal/CAS phases of the study have transitioned into a post-approval study to confirm the long-term functionality of transcatheter implantation of the Medtronic Harmony TPV.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

86 Participants Needed

123

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Gout clinical trials in Los Angeles, CA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Gout clinical trials in Los Angeles, CA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Gout trials in Los Angeles, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Los Angeles, CA for Gout is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Los Angeles, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Gout medical study in Los Angeles, CA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Gout clinical trials in Los Angeles, CA?

Most recently, we added Hip Arthroplasty for Femoral Neck Fracture, Tirzepatide + Retatrutide for Fatty Liver Disease and Parent Navigator Program for Congenital Heart Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in California

Anxiety Clinical Trials in California

Schizophrenia Clinical Trials in California

ADHD Clinical Trials in California

Bipolar Disorder Clinical Trials in California

Multiple Sclerosis Clinical Trials in California

Autism Clinical Trials in California

Treatment Resistant Depression Clinical Trials in California

Borderline Personality Disorder Clinical Trials in California

Social Anxiety Disorder Clinical Trials in California

Parkinson's Disease Clinical Trials in California

Alzheimer's Disease Clinical Trials in California

By Location

Clinical Trials near Los Angeles, CA

Clinical Trials near San Francisco, CA

Clinical Trials near San Diego, CA

Clinical Trials near Sacramento, CA

Clinical Trials near La Jolla, CA

Clinical Trials near Orange, CA

Clinical Trials near Stanford, CA

Clinical Trials near Palo Alto, CA

Clinical Trials near Long Beach, CA

Clinical Trials near Duarte, CA

Clinical Trials near Oakland, CA

Clinical Trials near Torrance, CA

Other People Viewed

By Subject

Top Clinical Trials near Brighton, MA

Top Clinical Trials near Cambridge, MN

Top Iga Nephropathy Clinical Trials

Top Diabetes Clinical Trials near Plano, TX

Top Clinical Trials near Joplin, MO

Top Clinical Trials near Dothan, AL

Top Idiopathic Intracranial Hypertension Clinical Trials

175 Clinical Trials near Emporia, KS

87 Clinical Trials near Kettering, OH

Top Clinical Trials near Delaware

148 Clinical Trials near Gillespie, IL

187 Clinical Trials near Clairton, PA

By Trial

OLX-07010 for Alzheimer's Disease Prevention

Paclitaxel for Breast Cancer

Sucrosomial Iron for Recovery After Cardiac Surgery

Dietary Intervention for Breast Cancer Risk Reduction

Decision Aid for Breast Cancer Surgery Choices

Immunotherapy for Kidney Cancer

Retifanlimab Combination Therapy for Endometrial Cancer

Chemotherapy + Immunotherapy for Esophageal Cancer

Evening Screen Time for Sleep Issues in Kids

Augmented Reality for Neck Surgery Preparation

Ladarixin + Sotorasib for Advanced Non-Small Cell Lung Cancer

Phacoemulsification vs miCOR System for Cataract Surgery

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial